The peptide stimulates the pancreas to release insulin only when blood glucose rises
Use of certain medications that may interact with B12 or choline metabolism (e.g., metformin, proton pump inhibitors, or anticholinergic drugs)
Many compounds that show promise in mice fail in human trials Not FDA-approved : 5-Amino-1MQ is not approved by any regulatory agency for any indication
TIER PLANS TIER 1 (10mg total) $199 total for 10 week supply Monthly cost breakdown: $80 Recommended if new to treatment or for those on 0.2-1mg/week TIER 2 (15mg total) $239 total for 10 week supply Monthly cost breakdown: $95 Recommended for those on 1.1-1.5mg/week TIER 3 (30mg total) $309 total for 10 week supply Monthly cost breakdown: $123 Recommended for those on 1.6mg/week and up MONTHLY PLANS Monthly Starter Dose $139 total for one month supply Recommended if new to treatment or for doses up to 0.75mg/week Monthly Mid Dose $159 total for one month supply Recommended for doses up to 1.25mg/week Monthly Advanced Dose $179 total for one month supply Recommended for doses of 1.3mg/week and up Hallandale Pharmacy - Semaglutide Injection Up to 90 days BUD
This is the gray market for peptides
LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al
